Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2014.918970